Institutional Investor Sells $6.67M in Shares Following Negative Clinical Trial Results
GOSS sits 22% above its 52-week low of $0.332 on elevated volume (7.1× avg).
Summary
An institutional investor sold $6.67 million worth of Gossamer Bio shares, reducing its stake to 1.7%, coinciding with the company's announcement of a failed Phase 3 clinical trial.
Key Events · Ownership and Investor Activity · GOSS
-
Significant Share Sale
Growth Equity Opportunities 18 VGE, LLC sold 17,093,034 shares of common stock at a weighted average price of $0.3906 per share, totaling approximately $6.67 million.
-
Reduced Ownership Stake
Following the sales, the reporting group's beneficial ownership decreased to 4,065,134 shares, representing 1.7% of the outstanding common stock.
-
Coincides with Negative Clinical Data
The sales occurred on February 23, 2026, the same day Gossamer Bio announced its Phase 3 PROSERA study for seralutinib missed its primary endpoint.
Analysis · GOSS · Life Sciences
Growth Equity Opportunities 18 VGE, LLC, an institutional investor affiliated with New Enterprise Associates, significantly reduced its stake in Gossamer Bio by selling 17.09 million shares for approximately $6.67 million. This substantial sale, representing nearly 7% of the company's market capitalization, occurred on February 23, 2026, the same day Gossamer Bio announced its Phase 3 PROSERA study for seralutinib in PAH missed its primary endpoint. The timing of this institutional selling, immediately after critical negative news, suggests a loss of confidence and could exert further downward pressure on the stock.
At the time of this filing, GOSS was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.1M. The 52-week trading range was $0.33 to $3.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.